



**FTSE
RUSSELL**
An LSEG Business

Mirati Therapeutics Inc (USA): Constituent Deletion

Changes in Russell Equal Weight Index Series

19 January 2024

Subject to the completion of the cash acquisition of Mirati Therapeutics Inc (USA, constituent) by Bristol Myers Squibb, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 1000 Equal Weight	24 January 2024*
Russell Midcap Equal Weight	24 January 2024

*In the absence of an active trading market, Mirati Therapeutics will be removed from the index at the cash acquisition terms of USD 58.00 for each share of Mirati Therapeutics stock held. Please note that FTSE Russell will remove Mirati Therapeutics at the cash terms only as a confirmed value for the CVR has not been announced.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at lseg.com/ftse-russell